Wouter W. De Herder

Wouter W. De Herder

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 250 publications

Safety of glucagon-like peptide-1 receptor agonists in neuroendocrine neoplasms.

Safety of glucagon-like peptide-1 receptor agonists in neuroendocrine neoplasms.

Journal: European journal of endocrinology
Published: March 03, 2026

[177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2-3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial.

[177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2-3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial.

Journal: EClinicalMedicine
Published: January 07, 2026

The effect of LysaKare infusion on serum potassium levels in patients with gastroenteropancreatic neuroendocrine tumours eligible for treatment with [177Lu]Lu-DOTA-TATE: A post-authorisation safety study.

The effect of LysaKare infusion on serum potassium levels in patients with gastroenteropancreatic neuroendocrine tumours eligible for treatment with [177Lu]Lu-DOTA-TATE: A post-authorisation safety study.

Journal: Journal of neuroendocrinology
Published: August 15, 2025

Somatostatin analogue continuation upon progression in patients with gastroenteropancreatic neuroendocrine tumour (SAUNA trial): a randomised controlled trial protocol.

Somatostatin analogue continuation upon progression in patients with gastroenteropancreatic neuroendocrine tumour (SAUNA trial): a randomised controlled trial protocol.

Journal: BMJ open
Published: July 04, 2025

Determining Prognosis in Patients With Carcinoid Syndrome: A Retrospective Single-Center Cohort Study.

Determining Prognosis in Patients With Carcinoid Syndrome: A Retrospective Single-Center Cohort Study.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: June 30, 2025

A Multicenter Phase II Randomized Controlled Trial Comparing 177Lu-Dotatate/Capecitabine Combination Treatment with 177Lu-Dotatate Monotherapy in Patients with Neuroendocrine Tumors.

A Multicenter Phase II Randomized Controlled Trial Comparing 177Lu-Dotatate/Capecitabine Combination Treatment with 177Lu-Dotatate Monotherapy in Patients with Neuroendocrine Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 09, 2025

Unravelling mesenteric fibrosis in small intestinal neuroendocrine tumours and implications for clinical management.

Unravelling mesenteric fibrosis in small intestinal neuroendocrine tumours and implications for clinical management.

Journal: Endocrine-related cancer
Published: April 10, 2025

A new link between insulinoma and congenital glucose-galactose malabsorption.

A new link between insulinoma and congenital glucose-galactose malabsorption.

Journal: Endocrine oncology (Bristol, England)
Published: March 24, 2025

Familial Mahvash disease with metastatic pancreatic NET and MEN1 mutations.

Familial Mahvash disease with metastatic pancreatic NET and MEN1 mutations.

Journal: Endocrine-related cancer
Published: March 19, 2025

Serum 5-Hydroxyindoleacetic Acid Measurements for the Diagnosis and Follow-up of Carcinoid Syndrome.

Serum 5-Hydroxyindoleacetic Acid Measurements for the Diagnosis and Follow-up of Carcinoid Syndrome.

Journal: The Journal of clinical endocrinology and metabolism
Published: January 27, 2025

Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours.

Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours.

Journal: Journal of neuroendocrinology
Published: July 31, 2024

Gut microbial and functional alterations lead to metagenomic signatures for midgut neuroendocrine tumor patients and for carcinoid syndrome.

Gut microbial and functional alterations lead to metagenomic signatures for midgut neuroendocrine tumor patients and for carcinoid syndrome.

Journal: Endocrine-related cancer
Published: June 27, 2024
Showing 1-12 of 250

Last Updated: 09/26/2026